SOURCE: Samaritan Pharmaceuticals Inc.

April 03, 2007 10:32 ET

Finding the Cure With Samaritan Pharmaceuticals' CEO Live on MN1.com

LAS VEGAS, NV -- (MARKET WIRE) -- April 3, 2007 -- Dr. Janet Greeson, Chairmen/CEO of Samaritan Pharmaceuticals, Inc. (AMEX: LIV), a developer of innovative drugs, will be featured live on Market News First (www.mn1.com) for an exclusive interview with the MN1 news team. The interview is scheduled for Tuesday, April 3, 2007, at 3:00 p.m. CDT.

The interview will highlight, for the investor, Samaritan Pharmaceuticals' recent accomplishments, including partnering its PII HIV Drug to Pharmaplaz and the recent advances in its pending Alzheimer's drug SP-233 (Caprospinol), among others.

Samaritan Pharmaceuticals focuses dually on the partnering of its promising innovative products to pharmaceutical companies, and the acquisition of the marketing and sales rights to revenue-generating marketed products for sales in Greece and Eastern Europe. This allows Samaritan to focus on its core competencies in drug discovery and drug development.

Join Dr. Greeson to learn more about the goals of the company, as well as its financials and its position in the stock market.

About Samaritan Pharmaceuticals:

Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company, focused on commercializing innovative therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, HIV, and Hepatitis C, as well as marketing and distributing nine marketed products, in Greece or various Eastern European countries.

http://www.samaritanpharma.com/html/videos.html

About MN1.com

Market News First is an online market news provider that brings investors current news on the market. Market News First is the only online, live radio web site that brings real market news to investors and features live interaction with companies from the AMEX, NYSE, NASDAQ, Over the Counter Bulletin Board and the Pink Sheets.

Through daily, live commentary we keep you up to date on the companies you invest in along with what's going on in the stock markets by the second.

Contact Information